172 Paucity of Events in the Long Term Follow Up Of Patients With Coronary Bifurcation Lesions Treated With Drug Eluting Stents

2012 ◽  
Vol 28 (5) ◽  
pp. S155-S156
Author(s):  
L. Ngunga ◽  
P. Cheung ◽  
S. Bundhoo ◽  
N. Brass ◽  
B. Tyrrell ◽  
...  
Keyword(s):  
Drug Eluting Stents ◽  
Coronary Bifurcation ◽  
Coronary Bifurcation Lesions ◽  
Long Term Follow Up ◽  
Drug Eluting ◽  
Bifurcation Lesions

scholarly journals Angiographic Restenosis in Coronary Bifurcations Treatment with Regular Drug Eluting Stents and Dedicated Bifurcation Drug-Eluting BiOSS Stents: Analysis Based on Randomized POLBOS I and POLBOS II Studies

2020 ◽  
Vol 2020 ◽  
pp. 1-8
Author(s):  
Robert J. Gil ◽  
Jacek Bil ◽  
Adam Kern ◽  
Luis A. Iñigo-Garcia ◽  
Radoslaw Formuszewicz ◽  
...  
Keyword(s):  
Stable Coronary Artery Disease ◽  
Optimization Technique ◽  
Drug Eluting Stents ◽  
Coronary Bifurcation ◽  
Coronary Syndrome ◽  
Angiographic Restenosis ◽  
Coronary Bifurcation Lesions ◽  
Drug Eluting ◽  
Bifurcation Lesions

Aim. The marked variation in bifurcation anatomy has brought about an ongoing search for stents specifically constructed for coronary bifurcations. This study aimed to analyze the angiographic restenosis prevalence and patterns and predictors of different patterns in dedicated bifurcation BiOSS® vs. current generation drug-eluting stents implanted in coronary bifurcation lesions based on data from two clinical trials POLBOS I and II. Methods. Dedicated bifurcation BiOSS® stents were compared with drug-eluting stents (DES) in patients with stable coronary artery disease (CAD) or nonST elevation acute coronary syndrome (NSTE-ACS) (POLBOS I: paclitaxel eluting BiOSS® Expert vs. DES; POLBOS II: sirolimus eluting BiOSS® LIM vs. DES). Provisional T-stenting was the default treatment. Morphological pattern of in-stent restenosis according to the modified Mehran classification adopted for bifurcation lesions was assessed with bifurcation dedicated quantitative coronary angiographic software (CAAS 5.11, Pie Medical Imaging BV, the Netherlands). Results. In total, 445 patients (222 patients in BiOSS group and 223 patients in DES group) were included into the analysis. In BiOSS group 24 cases of angiographic restenosis (10.8%) were recorded, and in DES group—17 cases (7.6%) at 12 months follow-up (angiographic control rate at follow-up—90.3%). In the BiOSS group most frequent medina classification in restenotic cases was 0.0.1 (25%), whereas in DES—0.0.1 and 0.1.1 (23.5% each). In multivariate regression analysis proximal optimization technique was associated with the lowest chance for restenosis (OR 0.15, 95% CI 0.06–0.33), whereas diabetes on insulin was associated with the highest risk of restenosis (OR 4.21, 95% CI 1.48–11.44). Conclusions. The angiographic restenosis pattern and rate was similar between BiOSS stents and DES in coronary bifurcation lesions.

scholarly journals Predictors of long-term outcomes of coronary bifurcation stenting: 6-year results from international, randomized POLBOS I and POLBOS II clinical trials

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
R.J Gil ◽  
A Kern ◽  
L.A Inigo Garcia ◽  
R.J Formuszewicz ◽  
S Dobrzycki ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Randomized Clinical Trials ◽  
Side Branch ◽  
Drug Eluting Stents ◽  
Target Vessel ◽  
Coronary Bifurcation ◽  
Drug Eluting ◽  
Bifurcation Lesions

Abstract Introduction Bifurcation lesions pose a therapeutic challenge during percutaneous coronary intervention (PCI). Results of regular drug-eluting stents (rDESs) in bifurcation treatment are not optimal. Purpose The aim of this study was to analyze the 6-year follow-up of BiOSS (Balton, Poland) stents in patients enrolled into two randomized clinical trials POLBOS I (NCT02192840) and POLBOS II NCT02198300). Methods The BiOSS stent is a coronary dedicated bifurcation balloon expandable stent made of 316L stainless steel and coated with a biodegradable polymer as well as the drug. The stent consists of two parts with different diameters connected with two struts of 1.9 - 2.5 mm length each. The aim of randomized POLBOS trials was to compare the BiOSS stents with regular drug eluting stents (rDES) in patients with stable CAD or NSTE-ACS (POLBOS I: paclitaxel eluting BiOSS Expert vs rDES; POLBOS II: sirolimus eluting BiOSS LIM vs rDES). Provisional T-stenting was the default strategy. Angiographic control was performed at 12 months in all patients. The primary end-point was composed MACE defined as cardiac death, myocardial infarction or target lesion revascularization (TLR). Clinical assessment was performed every year after index procedure. Results In POLBOS I trial BiOSS Expert was implanted in 120 patients (49.4%), and rDES was implanted in 123 patients. The target vessel was the left anterior descending (LAD) artery (52% vs 70%) followed by the left main stem (LMS) coronary artery (22% vs 15%). In rDES group, 38.2% of patients received paclitaxel-eluting stents. Side branch treatment with rDES was required in 10% of cases in both groups. At 12 months, the incidence of cumulative major adverse cardiovascular events (MACE) was similar in both groups: 13.3% vs 12.2% (P=0.7). The TLR rate was significantly higher in the BiOSS Expert group compared with rDES group (11.5% vs 7.3%; P=0.02). Significantly lower rates of restenosis were observed in final kissing balloon (FKB) subgroups of both the BiOSS Expert (8.1% vs 13.2%; P<0.05) and rDES groups (4.9% vs 9.5%; P<0.05). In POLBOS II 202 patients were randomly assigned 1:1 to treatment of the coronary bifurcation lesions either with the BiOSS LIM stent (n=102) or with rDES (n=100). The target vessel was the LAD (44% vs 43%) followed by the LMS (35.3% vs 38%). Side branch treatment was required in 8.8% (rDES) and 7% (BiOSS). At 12 months, the cumulative MACE incidence was similar in both groups (11.8% [BiOSS] vs. 15% [rDES, p=0.08]), as was the TLR rate (9.8% vs. 9% [p=0.8]). The binary restenosis rates were significantly lower in the FKBI subgroup of the BiOSS group (5.9% vs. 11.8%, p<0.05). At the time of ESC Congress 2020 we will present data from 6-year follow-up from POLBOS I trial and POLBOS II trial focusing on LM stenting and patients with diabetes. Conclusions BiOSS® stents provided satisfactory 1-year results which seemed comparable with rDES. Long-term data are pending. Funding Acknowledgement Type of funding source: None

Long-Term Follow-Up of Drug-Eluting Stents When Inserted for On- and Off-Label Indications

2007 ◽  
Vol 100 (11) ◽  
pp. 1619-1624 ◽  
Author(s):  
Asif Qasim ◽  
John Cosgrave ◽  
Azeem Latib ◽  
Antonio Colombo
Keyword(s):  
Drug Eluting Stents ◽  
Off Label ◽  
Long Term Follow Up ◽  
Drug Eluting

Orsiro: ultrathin bioabsorbable polymer sirolimus-eluting stent

2019 ◽  
Vol 15 (4) ◽  
pp. 295-300 ◽  
Author(s):  
Ofer Kobo ◽  
Ariel Roguin
Keyword(s):  
Clinical Performance ◽  
Drug Eluting Stents ◽  
Bioabsorbable Polymer ◽  
Coronary Syndrome ◽  
Long Term Follow Up ◽  
Potential Benefits ◽  
Drug Eluting ◽  
Sirolimus Eluting Stent

Recent stent developments aimed to reduce and eliminate the long-term inflammatory response include thinner struts, modifications to stent design and the development of bioresorbable polymers (BP). We aimed to summarize the main findings and to discuss the established and the potential benefits of the Orsiro BP sirolimus-eluting stents in everyday clinical use. We have reviewed the available evidence on the clinical performance of the Orsiro BP drug-eluting stents. Orsiro BP sirolimus-eluting stents is clinically proven and showed noninferiority against major drug-eluting stents and provides high safety and efficacy profile at long-term follow-up. Furthermore, it may be the preferred treatment option in specific subgroups as acute coronary syndrome, as shown in the BIOFLOW V trial.

Early beneficial effects of drug-eluting stents in vein grafts wane during long term follow-up

2012 ◽  
Vol 80 (7) ◽  
pp. 1112-1117 ◽  
Author(s):  
Vincenzo Pasceri ◽  
Giandomenico Tarsia ◽  
Giampaolo Niccoli ◽  
Nicola Viceconte ◽  
Italo Porto ◽  
...  
Keyword(s):  
Drug Eluting Stents ◽  
Vein Grafts ◽  
Beneficial Effects ◽  
Long Term Follow Up ◽  
Drug Eluting
Sign in / Sign up

Export Citation Format

Share Document